For the Inventor, By the Inventor

Enter assignee name

San Diego, CA, United States of America

Histogen, Inc.

USPTO Granted Patents = 12

% Expired Patents = 33.3

CIPO Patents = 5

EPO Patents = 3

Forward Citations = 48

Loading Chart...

Loading Chart...

13 inventors (with patents filed for the assignee):

Gail K Naughton (10 out of 48 patents)

Mark Baumgartner (6 out of 9 patents)

Kyle Nickey (6 out of 7 patents)

4. Emmett Pinney (4 out of 6 patents)

5. Frank Ziegler (4 out of 5 patents)

6. Francis C Zeigler (2 out of 4 patents)

7. Alfred P Spada (2 out of 52 patents)

8. Robert J Ternansky (1 out of 35 patents)

9. Michael Mueller (1 out of 2 patents)

10. Robert J Temansky (1 out of 2 patents)

11. Frank Ziegler (0 patent)

12. Frank Zeigler (0 patent)

13. Mark Baumgartner (0 patent)

14. Frank Zeigler (0 patent)

12 patents: Sort by Forward Citations

1. 11597703 - Caspase inhibitors and methods of use thereof (2023-03-07),

2. 11447497 - (S)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating cardiovascular diseases (2022-09-20),

3. 11274276 - Conditioned medium and extracellular matrix compositions from cells cultured under hypoxic conditions (2022-03-15),

4. 10538736 - Conditioned medium and extracellular matrix compositions from cells cultured under hypoxic conditions (2020-01-21),

5. 10143708 - Extracellular matrix compositions for the treatment of cancer (2018-12-04),

6. 9512403 - Conditioned medium and extracellular matrix compositions from cells cultured under hypoxic conditions for methods of treating tissue injury (2016-12-06),

7. 9506038 - Extracellular matrix compositions for the treatment of cancer (2016-11-29),

8. 9034312 - Extracellular matrix compositions for the treatment of cancer (2015-05-19),

9. 8852637 - Extracellular matrix compositions for the treatment of cancer (2014-10-07),

10. 8535913 - Soluble composition for promoting hair growth produced by hypoxic culture of fibroblasts cells (2013-09-17),

11. 8530415 - Repair and/or regeneration of cells with a composition produced by culturing fibroblast cells under hypoxic conditions (2013-09-10),

12. 8524494 - Low oxygen tension and BFGF generates a multipotent stem cell from a fibroblast in vitro (2013-09-03),

Histogen, Inc. is a regenerative medicine company focused on developing therapies that stimulate the body's own stem cells to regenerate tissues and restore youthful function. The company's innovative technology platform utilizes proteins and growth factors to activate stem cells in the body, offering potential therapeutic solutions for a wide range of medical conditions. Through their research and development efforts, Histogen aims to revolutionize the field of regenerative medicine and improve the lives of patients worldwide.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

12 Patents

#447 in San Diego, CA

#6,055 in California

#25,526 in US

#48,090 in the World

San Diego, CA, United States of America

Histogen, Inc.

Forward Citations = 48

13 inventors:

Gail K Naughton (10 out of 48 patents)

Mark Baumgartner (6 out of 9 patents)

Kyle Nickey (6 out of 7 patents)

4. Emmett Pinney (4 out of 6 patents)

5. Frank Ziegler (4 out of 5 patents)

Please report any incorrect information to [email protected]

Loading…